

Poster Index - 2024 Oligo Meeting | Montreal | Canada (updated 16 September)

Poster #	Title	First Name	Last Name	Affiliation
P001	Targeting Aminoacidase-Semialdehyde Synthase (AASS) Using Antisense Oligonucleotides (ASO) as a Novel Therapeutic Approach for Pyridoxine-Dependent Epilepsy (PDE)	Muna	Abedrabbo	University of British Columbia
P002	Chemical Synthesis & Biological Evaluation of RNA Mimics with Preserved 2'-OH Groups	Abhishek	Abhishek	McGill University
P003	Development of network theory and AI-based drug discovery platform: an example of microRNA therapy for cardioprotection	Bence Károly	Ágg	Cardiometabolic and HUN-REN-SU System Pharmacology Research Group, Center for Pharmacology and Drug Research & Development, Department of Pharmacology and Pharmacotherapy, Semmelweis University
P004	Sequence-specific recognition of double-stranded DNA using parallel-stranded peptide nucleic acids	Yuichiro	Aiba	Department of Chemistry, Graduate School of Science Nagoya University
P005	Antisense oligonucleotides targeting regulatory RNAs to upregulate ornithine transcarbamylase (OTC) gene expression	Brynn	Akerberg	CAMP4 Therapeutics Corp.
P006	Targeting Transferrin Receptor to Transport Antisense Oligonucleotides Across the Blood-Brain Barrier	Padma	Akkapeddi	Denali Therapeutics
P007	Developing siRNA to Modulate HTT mRNA Isoforms	Sarah	Allen	UMass Chan Medical School
P008	Quantitative assessment of RNA modifying enzyme content in tissues	Harvey	Andersen	Eli Lilly
P009	Development of a Rodent Model Sensitive to Neurotoxic Effects of Antisense Oligonucleotides	Raúl	Andrés Santamaría	Central Animal Facility, Leiden University Medical Center
P010	Mastering and Accelerating sgRNA Synthesis: Unveiling Success Strategies	Yvonne	Angell	WuXi TIDES, WuXi AppTec (HongKong) Limited
P011	Synthesis and Structure-Activity Relationship of MicroRNA Inhibitory Oligonucleotides Composed of Bridged Nucleic Acids	Tomo	Araki	Mitsubishi Tanabe Pharma America, Inc.
P012	Bioanalysis of Oligonucleotide Therapeutics from Tissue Samples	Makda	Araya	Waters Corporation
P013	Optimizing Ocular Gene Therapy: Harnessing the Potential of the Proteolipid Vehicle Nucleic Acid Delivery Platform	Tejal	Aslesh	Entos Pharmaceuticals
P014	RNA-seq-based Nucleic Acid Therapeutics Lead Optimization	Nadine	Assmann	Axolabs GmbH
P015	Fluorine-Modified CRISPR-Cas12a crRNA for Gene Editing	Halle	Barber	McGill University
P016	An Oligonucleotide Transport Vehicle for the Treatment of Neurodegenerative Disease	Scarlett	Barker	Denali Therapeutics
P017	Click chemistry applications of vinyl-modified siRNA	Kaleena	Basran	McGill University
P018	Reprogramming DNA with a Small Molecule	Jessica	Bennett	McGill University
P019	Development of DNA Aptamers for Visualization of Glial Brain Tumors and Detection of Circulating Tumor Cells	Maxim	Berezovski	University of Ottawa
P020	CGS-15943 co-treatment enhances the activity of multiple ASO platforms	Scott David	Bittner	Department of Biomedical Sciences, Carlson College of Veterinary Medicine, Oregon State University
P021	Tissue-specific, sustained delivery of antisense oligonucleotides via a novel, injectable biomaterial	Unnur	Björgvinsdóttir	Technical University of Denmark
P022	From pixels to insights: Illuminating mRNA escape from lipid nanoparticles by the single particle	Sara Vogt	Bleshøy	Department of Chemistry & Nanoscience Center, UCPH
P023	20-hydroxyecdysone improves antisense-mediated exon-skipping efficacy for the treatment of Duchenne Muscular Dystrophy	Mathilde	Blitek	UVSQ

P024	A humanized knock-in Col6a1 mouse models an intronic splice variant and allows testing of human-ready exon-skipping therapies	Veronique	Bolduc	Neuromuscular and Neurogenetic Disorders of Childhood Section, National Institute of Neurological Disorders and Stroke, National Institutes of Health
P025	Evaluation of RISC-loaded siRNA PK to Improve In Vitro-In Vivo Correlation (IVIVC) of siRNA Therapeutics	Caroline	Bosmajian	University at Buffalo
P026	PS to PO Impurity Analysis and Accompanying Solutions for Fully Modified Guide Strand siRNA Oligonucleotides	Brianna	Bramato	UMass Chan Medical School
P027	High-Throughput Single-Particle Analysis of Lipid Nanoparticle Biophysical Properties: A Novel Approach for Enhancing LNP Therapeutic Design	Artu	Breuer	University of Copenhagen
P029	Precision Gene Delivery to the Lungs via Optimized Fusogenic Proteolipid Vehicles	Douglas	Brown	Entos Pharmaceuticals
P030	Identification of Protein Complexes Formed By RNAi Factors in Chromatin	Rut	Bryl	UT Southwestern Medical Center
P031	Spliceosome-mediated RNA trans-splicing prevents the pathogenic phosphorylation of ataxin-1	Ronald	Buijsen	LUMC
P032	From concept to development: progressing Sapreme's unique endosomal escape enhancer platform to selection of a first development program in DMD	Miriam	Bujny	Sapreme Technologies
P033	Chemistry Matters: Morpholino Oligomers Offer Safer Splice Modulation	Jessica	Cale	Centre for Molecular Medicine and Innovative Therapeutics, Health Futures Institute, Murdoch University
P034	Peptide-Conjugated Phosphorodiamidate Morpholino Oligomers for the Treatment of Late-Onset Pompe Disease	Perla	Castaneda	Sarepta Therapeutics
P035	Enabling Personalized Splice-Switching Oligonucleotide Therapies using an RNA Foundation Model	Albi	Celaj	Deep Genomics
P036	Characterization of triterpene-mediated endosomal escape of cholesterol siRNA	Myriam	Cerezo	Lund University
P037	Advancements and Challenges in LC-MS-Based Bioanalysis of Oligonucleotides: Improving Quantification and Characterization of Duplexed RNAs for Drug Development	Megha	Chandrashekar	Amgen
P038	Engineering Physicochemical Properties of Nucleic Acid Nanoparticles for Enhanced Pharmacokinetic Profiles	Hiroyuki	Chaya	Massachusetts Institute of Technology
P039	Developing an Approach to Screening Rare Genetic Diagnoses for Amenability to Bespoke Antisense Oligonucleotide Therapy Development	David	Cheerie	University of Toronto
P040	Quantitative Bioanalysis of HT-KIT Vivo-Morpholino Using Hybridization LC-MS/MS	Mingluan	Chen	Altasciences
P041	Utilizing a pH-responsive nucleobase-modified DNA aptamer to selectively inhibit cancer cell migration	Yuyuan	Chen	Department of Chemistry and Biotechnology, The University of Tokyo
P042	BODIPY-Tri-GalNAc Conjugate for Fluorescence Polarization-Based ASGPR Binding Assays	Chen-Yun	Chen	Development Center for Biotechnology
P043	Understanding the drivers of extra-hepatic non-viral delivery of nucleic acid-based molecules	Herbert	Chiou	Generation Bio
P044	The siRNA-saRNA relationship: substrate suitability for chemical modifications	Virginia	Chiu	Faculty of Science Ontario Tech University
P045	Discovery and characterization of stereodefined PMO-gamers targeting tau	Hyeong-wook	Choi	Eisai Co.
P046	Validation of a Hybridization ELISA Method for the Determination of an Antisense Oligonucleotide in Human Cerebrospinal Fluid using a Surrogate Method	Katherine	Cleroux	Charles River Laboratories
P047	Understanding and predicting nucleic acid therapeutics activity and toxicity in healthy and diseased cardiac models.	Marguerite	Colin	MRC Toxicology Unit, University of Cambridge

P048	A novel strategy to treat Fibrodysplasia Ossificans Progressiva with therapeutic small interfering RNAs in a SNP selective manner	David	Cooper	UMass Chan Medical School
P049	An antisense antibiotic candidate with unexpected bactericidal activity against several different fusobacteria species	Valentina	Cosi	Helmholtz Institute for RNA-based Infection Research (HIRI)
P050	Validation of a Duplex One-Step RT- qPCR method for the quantitative determination of a target mRNA transcript expression level in non-human primates	Obed	Coulibaly	Charles River Laboratories
P051-V	Isoform-specific siRNAs as a potential therapeutic approach for Tau-dependent Neurodegenerative diseases.	Giuseppina	Covello	Department of Cellular, Computational and Integrative Biology (CIBIO), University of Trento
P052	Targeted Delivery of siRNA to Proximal Tubule Cells in Kidney	Jeremy	Cunniff	Judo Bio
P053	Anti-CRISPR Click Chemistry – A Novel Route to Small Modified Nucleic Acid-Based Inhibitors (SNUBs) of CRISPR-Cas9	Michael	Cunningham	McGill University
P054	Engineering small molecules endosomal escape enhancers for improving oligonucleotide therapeutic window	Anders	Dahlén	AstraZeneca R&D Gothenburg
P055	Modifying Size and Hydrophobicity of Monovalent siRNA Conjugates Impacts PK/PD Properties	Christopher	Dahlke	UMass Chan Medical School
P056-V	Modulation of TNPO3 expression in limb-girdle muscular dystrophy D2 (LGMD2) cells.	Paola	Dalgo	Chronic diseases group, Department of Health Sciences, University Técnica Particular de Loja.
P057	Characterizing the cellular interaction of DNA conjugates from in-vitro to in-vivo	Trishalina	Das	McGill University
P059	RNA interference through single-stranded hairpin loop RNAs (loopmeRNAs)*	Dhrubajyoti	Datta	Alnylam Pharmaceuticals
P060	Pioneering Nucleic Acid-Based Therapies with STAAR Ionizable Lipids: Effective Lung Delivery and Exceptional In Vivo Performance	Laura	de Miguel Acha	Certest Biotec
P061	Targeted Delivery of ACE-tRNAs for Suppression of Premature Termination Codons Using Patented Ionizable Lipid Nanoparticles	Laura	de Miguel Acha	Certest Pharma
P062	Chimeric Molecules: A screening Platform to Combine Peptides and Oligonucleotides for Targeted Therapeutics	Laura	de Miguel Acha	Certest Pharma
P063	Discovery and mitigation of side product formation during synthesis of a new GalNAc tether for siRNA conjugation using Strain-promoted azide-alkyne cycloaddition (SPAAC).	Alexandre	Debacker	e-therapeutics
P064	The Robust, High-Yielding, Chemical Synthesis of RNA and Modified RNA to 300 Nucleotides in Length using 2'-O-Thionocarbamate-Protected Nucleoside Phosphoramidites on the Solid Phase	Douglas	Dellinger	University of Colorado
P065	Structure-Guided Design of Nucleic Acid-Based Cas9 Inhibitors	Ashmita	Dhokal	Wake Forest School of Medicine
P066	Diastereomeric inhomogeneity in Mogensen batches correlates with their biological activity	LORENZO	DI BARI	University of Pisa, Dpt. of Chemistry and Industrial Chemistry
P067	Stimuli responsive delivery of oligonucleotides using Metal Organic Framework Nucleic Acid Nanocapsules (MOF-NANs)	Divya	Divya	University of Connecticut
P068	Enhancing the Activity and Delivery of Oligonucleotide Therapeutics with Modified Phosphoramidites and Nucleotides	Daniel	Dixon	Thermo Fisher Scientific
P069	Antiparallel clamps: Suitable probes for detecting pyrimidine sequences through triplex formation	Arnau	Domínguez	CSIC
P070	Splice-modulating antisense oligonucleotides targeting a pathogenic variant in adult polyglucosan body disease (APDB) corrects mis-splicing and ameliorates protein deficiency in patient cells	julie	douville	n-Lorem Foundation
P071	Design considerations towards a RIG-I adjuvanted CMV mRNA vaccine	Svenja	Dudek	Institute for Clinical Chemistry and Clinical Pharmacology

P072	Efficacy in a Preclinical Model of Alcohol Use Disorder with a GalXC siRNA Targeting ALDH2	Henryk	Dudek	Novo Nordisk
P073	High-Throughput Screening in Search of RNA Splicing Modulators Using a HiBiT Assay	Sarah	Duellman	Promega Corporation
P074	Development of a Hybridization LC-MS Methodology for Quantitation of siRNA in Cynomolgus Monkey	Jean-François	Dupuis	Altasciences
P075	Comparing Traditional and Duplex-Based HPLC Methods for Enhanced Manufacturing Efficiency of Branched siRNAs	Dimas	Echeverria	UMass Chan Medical School
P076	Innovations in Oligonucleotide Therapeutics Manufacturing to Responsibly Meet Future Demand	Ramon	Espinoza-Lewis	Sylentis SAU
P077	Strategic Modification of DNA Nanocubes for Improved Biological Activity	Sinan	Faiad	McGill University
P078	Potent and Durable gene modulation in heart and muscle with chemically defined siRNAs	Hassan	Fakih	RNA Therapeutics Institute - UMass Chan Medical School
P079	Elucidating the Potential Feedback Mechanism Between PIK3C3 and TBC1D2 in Oligonucleotide Drug Delivery	Linda	Fatumoju	University of Nebraska
P080	Manipulating the bioactivities of a gut microbiota model bacterium with antisense nucleic acids	Taís	Franco de Carvalho	Würzburg University
P081	Assessing the Safety of Antisense Oligonucleotides Through Interrogating Changes in the RNA-Binding Proteome.	Alex	Fulton	Cambridge University/MRC Toxicology Unit
P082	Identification and validation of new intracellular protein partners of phosphorothioate-splice switching oligonucleotides in skeletal muscle cells	Aris	Gaci	Université Paris-Saclay, UVSQ, Inserm, END-ICAP
P083	One for all: a promising therapeutic strategy to safely remove multiple deep-intronic variants in ABCA4.	Alex	Garanto	Radboud university medical center, Department of Human Genetics
P084	Artificial siderophores as carriers of antibacterial antisense oligonucleotides	Chandradhish	Ghosh	Helmholtz Institute for RNA-based Infection Research (HIRI)
P085	In-vivo screening of barcoded LNPs delivered through systemic circulation	Soumitra	Ghosh	Genentech
P086	Design of next generation oligonucleotides: Magellan's paradox	David	Gilot	Mechanistic and Structural Biology, Discovery Sciences, R&D, AstraZeneca
P087	First-in-human study to evaluate the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of RBD4059, a GalNAc-siRNA drug targeting coagulation factor XI (FXI), in healthy subjects	Felix	Gnerlich	Ribocure Pharmaceuticals AB
P088	Diversifying chemical modifications and conjugations of ASOs promoting exon skipping for Duchenne Muscular Dystrophy	Emma	Groenwold	McGill University
P089	Development of a combinatorial siRNA therapy for the treatment of fibrodysplasia ossificans progressiva	Katie	Gross	RNA Therapeutics Institute - UMass Chan Medical School
P090	Effect of CRISPR RNA 2' Sulfur Substitutions on Cas9 Activity	Venkatesh	Gude	Biochemistry, School of Medicine, Wake Forest University
P091	Sequence confirmation and impurity characterization of therapeutic oligonucleotides	Felizia	Guye	Bachem
P093	Bespoke antisense oligomer-mediated splice modulating therapies for recessive dystrophic epidermolysis bullosa patients	Kristin	Ham	Centre for Molecular Medicine and Innovative Therapeutics, Health Futures Institute, Murdoch University
P094	Probing Z-DNA/Z-RNA stability and their protein recognition through chemical modifications	Harneesh Kaur	Harneesh Kaur	McGill University
P095	In Silico-Guided Selection of Target Sequences for RNase H1-Dependent Antisense Oligonucleotides	Emilio	Harris-Mostert	Clinical Genetics Department, Erasmus Medical Center
P096	Deep Learning and 4D imaging Reveals Intracellular delivery and Escape of Oligonucleotides"	Nikos	Hatzakis	UNIVERSITY OF COPENHAGEN
P097	In Vivo Multiplexed Discovery of Antibody-oligonucleotide Conjugates to Drive Gene Knockdown in the CNS	Glenn	Hauk	Manifold Bio
P098	Experimental systems to dissect siRNA off-target mechanisms	Judith	Hauptmann	Silence Therapeutics GmbH

P099	Application of supercritical fluid chromatography to deamination analysis of oligonucleotides	Momoka	Hayashida	Shimadzu Corporation
P100	Intracellular dose-response determination of siRNA by two-tailed RT-qPCR of electroporated cells	Hampus	Hedlund	Lund University, Department of Clinical Sciences, Section for Oncology and Pathology
P101	Evaluation of various bioanalytical methods to assess the sensitivity, selectivity and linearity of Antisense oligonucleotide (ASO) quantification in cerebrospinal fluid CSF samples	Helene	Helene	Institut de Recherche Servier Paris-Saclay
P102	Oligonucleotide Structural Evolution Analysis	Keith	Hermann	Axolabs
P103-V	Enhancing Purification of Messenger RNA Drug Substances: Exploring Macroporous Resin Particles for Improved Separation from Immunostimulatory Double-Stranded RNA Impurities	Yuki	Higuchi	YMC CO., LTD.
P104	Elucidating the impact of nuclear RNAi in chromatin	Cristina	Hofman	UT Southwestern Medical Center
P105	Nonclinical Data for PGN-EDODM1 Demonstrated Mechanistic and Meaningful Activity for the Potential Treatment of DM1	Ashling	Holland	PepGen
P106	Single- and Repeat-Dose Nonclinical Data for PGN-EDO51 Demonstrated Favorable Pharmacology and Safety Profiles for the Treatment of DMD	Ashling	Holland	PepGen
P107	Nonclinical in vitro and in vivo data demonstrated low immunogenicity risk and favorable profile of PGN-EDO51 for the treatment of DMD	Ashling	Holland	PepGen
P108	Knockdown of transcription factor C/EBPbeta suppresses tumor metastasis in triple-negative breast cancer in a hypoxia model	Kevin	Holm	City of Hope
P109	Development of the polymerase mutants towards screening of functional oligonucleotides using bridged nucleic acids containing an amide bond or a guanidino group.	Hidekazu	Hoshino	National Institutes of Biomedical Innovation, Health and Nutrition (NIBIOHN)
P110	Characterization of DNA specific aptamers for Acute myeloid leukemia cells using whole cell-SELEX	Bahareh	Hosseinpour	Carleton University, Department of Chemistry,
P111	cis-4'-Spirocyclobutyl Phosphonate: A Novel Conformational Locked Phosphate Mimic at the 5'-end of siRNA Guide Strand To Enhance In Vivo Potency and Duration	Jinyu	Huang	Rona Therapeutics
P112	SORT1 targeting small molecule conjugate enhances brain bio-distribution and efficacy of siRNA drugs	Jinyu	Huang	Rona Therapeutics
P113	Individualized antisense oligonucleotide therapy for Niemann-Pick disease type C	Yu-Han	Huang	Division of Genetics and Genomics, Boston Children's Hospital
P114	INVESTIGATING THE PHARMACOLOGICAL PROFILE OF THERAPEUTIC OLIGONUCLEOTIDES IN THE LUNG	Lulu	Huang	Ionis Pharmaceuticals
P115	Developing a Peptide-mediated Mechanism for siRNA Delivery to Podocytes	Sungwon	Hwang	ProteinQure
P117	Versatile Gene Expression Increase Technology: RNA Hacking Targeting the 3'UTR	Yua	Itsuki	Kumamoto Univ.
P118	Rapid High-Throughput On-Column Gas-Phase Deprotection and Purification of Therapeutic Oligonucleotides for In Vitro Use	Samuel	Jackson	UMass Chan Medical School RNA Therapeutics Institute - Khvorova Lab
P119	Comparison of two Bioanalytical Assays – PNA-HPLC Assay and LC-MS/MS	Thessa	Jacob	Axolabs GmbH
P120	Tolerability of Huntingtin Lowering - Learnings from Nonhuman Primates	Maja	Janas	Alnylam Pharmaceuticals
P121	Targeting the necroptosis pathway by downregulating MLKL expression with antisense oligonucleotides	Frank	Jaschinski	Secarna Pharmaceuticals GmbH & Co. KG
P122	Novel siRNA for topical treatment of retinal diseases: Nonclinical and clinical development	Ana Isabel	Jimenez	Sylentis
P123	Evaluation of ASO's in a 3D-tissue engineered skeletal muscle model for FSHD	Silvana	Jirka	LUMC
P124	Tracking subcellular localization of siRNA after cytosolic entry	Johanna	Johansson	Lund University, Department of Clinical Sciences, Section for Oncology

P125	Development of oligonucleotide heteroduplexes for synergistic gene upregulation of SCN1A to combat Dravet syndrome	Aswathy	Joji	Department of Chemistry, University of Miami
P126	DeepADAR: A deep learning approach to model regulatory principles of ADAR-based RNA editing and its application to gRNA design	Andrew	Jung	Deep Genomics
P127	Significant Seizure Reduction in Pediatric Participants with Early Onset SCN2A Developmental and Epileptic Encephalopathy following Treatment with Elsunersen, a Novel Antisense Oligonucleotide: Findings from the EMBRAVE Study	Kris	Kahlig	Praxis Precision Medicines
P128	Development of novel luminescent assays for sensitive and specific quantitation of double-stranded RNA in RNA therapeutics	Alissa	Kamens	Promega Corporation
P129	Lipid Nanoparticle Formulations for the Delivery of CpG-STAT3 siRNA to Myeloid Immune cell for Cancer Immunotherapy	Elaine	Kang	Beckman Research Institute at City of Hope
P130	The role of telomere as a therapeutic target in malignant and glioma cancer stem cells	Elaine	Kang	Beckman Research Institute at City of Hope
P131	Bi-functional CpG-DNMT1 inhibitor for the treatment of acute myeloid leukemia	Damian	Kaniowski	Department of Immuno-Oncology, Beckman Research Institute at City of Hope Comprehensive Cancer Center
P132	REPRESS: Predicting Tissue-Specific microRNA-RNA Interactions for Therapeutic Design using Deep Learning	Bhargav	Kanuparthi	Deep Genomics
P133	Purification of Human ADAR Enables Evaluation of Oligo-Directed RNA Editing in a Cell Free Environment that Predicts In Vivo Activity	Agya	Karki	Korro Bio
P134	WISPER from the Heart: Targeting a Cardiac Myofibroblast-specific lncRNA to Treat Cardiac Fibrosis	James	Karras	HAYA Therapeutics
P135	Regulation of Target Gene Expression Levels Using Next-Generation Nucleic Acid Medicine	Yousuke	Katsuda	Kumamoto Univ.
P136	Validation of Mechanisms for Mitigating Central Nervous System Toxicity of Antisense Oligonucleotides by Heteroduplex Oligonucleotide Technology	Maho	Katsuyama	Department of Neurology and Neurological Science, Tokyo Medical and Dental University
P137	Stabilization of self-assembled sequence-defined DNA conjugates using UV irradiation	Sepideh	Kaviani	McGill University
P138	Scalable One-Pot Liquid Phase Oligonucleotide Synthesis Enhanced by Organic Solvent Resistant Membrane Filtration	Ronan	Kelly	University College Dublin
P139	Identification of Proteins Modulating ASO Activity in Glioblastoma	Alexandre	Khuu	Servier Research Institute
P140	Therapeutically targeting the classical complement pathway with antisense oligonucleotides in Alzheimer's disease	Lukasz	Kielpinski	F. Hoffmann-La Roche Ltd
P141	A n-of-1 multi-disciplinary drug development approach for a patient with a neurodevelopmental disorder	Barbara	Killian	Charles River Laboratories
P142	Development of an ASO therapy for a patient with a KCNQ3/ Kv7.3 disorder	Barbara	Killian	Charles River Laboratories
P143	Benchmarking Nucleic Acid Nanoparticles for Hepatocytic siRNA Delivery	Andy	Kim	MIT
P145	Leveraging PAT for Process Understanding and Control Strategy during Development and Manufacturing of Oligonucleotides	Sungwon	Kim	ST Pharm
P146	Lipid-stapled Oligonucleotide Supramolecular Structures: Baits for Anticancer Therapeutic Application	Faith	Kivunga	University of Bordeaux
P147	Investigating nucleic acid nanoparticle biodistribution in the central nervous system for nucleic acid therapeutic delivery	Grant	Knappe	Massachusetts Institute of Technology

P148	Thiomorpholino Oligonucleotides (TMOs): A Versatile Tool for Gene Expression Regulation and Therapeutic Applications	Ondrej	Kostov	University of Colorado Boulder
P149	UPREGULATING CEBPA EXPRESSION IMPROVES THE ANTI-LEUKEMIC ACTIVITY OF A TYROSINE KINASE INHIBITOR	Olivia	Kovecses	McGill University
P150	Targeting AURKA with Splice-switching Antisense Oligonucleotides in PDAC	Alexander	Kral	Cold Spring Harbor Laboratory
P151	P-N backbone-containing siRNAs synthesized using H-phosphonate chemistry	Jayanta	Kundu	Alnylam Pharmaceuticals
P152	Splice-modulating antisense oligonucleotides for RFX3-haploinsufficiency associated neurodevelopmental disorder	Jenny	Lai	Boston Children's Hospital
P153	Versatile in vitro toolbox for disease modeling, ASO-screening, and neurotoxicity studies	Marlen	Lauffer	Leiden University Medical Center
P154	Deciphering and overcoming off-target AMPAR inhibition of anti-miR oligonucleotide RGLS4326	Edmund	Lee	Regulus Therapeutics
P155-V	Development of a cell-penetrating asymmetric siRNA targeting MyD88 for advanced age-related macular degeneration	Yuyoung	Lee	OliX Pharmaceuticals, Inc.
P156-V	Novel cell-penetrating asymmetric siRNA platform for potent and sustained gene silencing in the extrahepatic tissues	Yuyoung	Lee	OliX Pharmaceuticals, Inc.
P157	Lessons from N-of-1 trials: a retrospective review of clinical protocols, efficacy and safety data, and oversight processes for N-of-1 studies, from milasen until today.	claudia	lentucci	Division of Genetics and Genomics, Boston Children's Hospital
P158	Durable Exon Skipping and Dystrophin Production with Endosomal Escape Vehicle (EEV™) - Oligonucleotide Conjugates in Preclinical Models of DMD	Xiang	Li	Entrada Therapeutics
P159	Elucidating the Roles of Argonaute Proteins in Mediating GalNAc-siRNA Off-target Activity and Hepatotoxicity	Hongda	Li	Ionis Pharmaceuticals
P160	Development of 3D-printed reusable solid support for short-chain oligonucleotide synthesis systems	Ming-Chun	Lin	Industrial Technology Research Institute
P162	Impurity Profiling and Characterization of Oligonucleotides Using LCMS-SQ and MALDI	Suzuki	Lisa	Shimadzu Scientific Instruments Inc.
P163	Next-Generation LNPs Induce Effective Anti-Tumor T cell Responses	Jun	Liu	Providence Therapeutics Holdings, Inc.
P164	N-of-1 for N-of-Many: comprehensive, scalable development of patient-customized splice modulation ASOs for Ataxia Telangiectasia	Clemens	Lochmann	Hertie-Institute for Clinical Brain Research
P165	NB22: A deep learning-designed peptide-siRNA conjugate that targets lung epithelial cells implicated in IPF	Kyler	Lugo	Nosis Biological Sciences, Inc.
P166	Towards development of VH single-domain-oligonucleotide conjugates as carriers for oligonucleotide therapeutics into tissue and cellular targets	Omer	Lustgarten	Nucleic Acid Therapy Accelerator (NATA), Medical Research Council, Harwell Campus
P167	Validating chemically modified siRNA targeting SARM1 in vitro and in vivo; validating chemically modified siRNA targeting SARM1 in vitro and in vivo	Eric	Luu	UMass Chan Medical School
P168	Chemical synthesis of branched RNA inhibitors of the lariat debranching enzyme (Dbr1)	Zidi	Lyu	McGill University
P169	Modulating neuroinflammation associated with APOE silencing in Alzheimer's Disease using fully chemically modified oligonucleotides.	Allison	Maebius	UMass Chan Medical School
P170	Conditional release of chemically modified oligonucleotides without kinetic compromise	Tracy	Mallette	University of Washington
P171	Genetic screening using CRISPR/Cas9 discovers genes that influence ASO activity	Liza	Malong	Hoffman La Roche
P172	Advancing Nucleic Acid-Based Medicines Through Innovation and Partnerships at Roche	Shiksha	Mantri Mottet	F. Hoffmann-La Roche Ltd
P173	CRISPR-based gene editing to restore correct splicing in erythropoietic protoporphyria	Eva-Maria	Manz	ETH Zurich

P174	Building a specialized development candidate selection process for antisense oligonucleotides targeting lncRNAs	Maria	Marcuello	HAYA Therapeutics SA
P175	Direct observation of lipid nanoparticles loading efficiency, release kinetics, and cellular entry pathways by single particle studies	Stavroula	Margaritaki	Department of Chemistry, University of Copenhagen
P176	Structure-Activity Relationship Studies of Antibody-Phosphorodiamidate Morpholino Oligomer Conjugates for Duchenne Muscular Dystrophy (DMD)	Isaac	Marks	Avidity Biosciences, Inc.
P177	Modulation of PARP1 Expression with Therapeutic Oligonucleotides in Acute Myeloid Leukemia	Bruktawit	Maru	McGill University
P178	DG9 peptide enhances nuclear delivery of PMO in cardiac and systemic tissue, increasing efficacy in heart and CNS in DMD and SMA mouse models	Rika	Maruyama	University of Alberta
P179	Key drivers of nuclear uptake of unconjugated antisense oligonucleotides in primary human hepatocytes	Cecile	Mathieu	CAMP4 Therapeutics Corp.
P180	INTASYL self-delivering RNAi: a flexible platform for cancer treatment	Melissa	Maxwell	Phio Pharmaceuticals
P181	Developing optimized siRNA conjugates for in vivo delivery	Sean	McCauley	Advirna
P182	Selection of DNA aptamers that prevent the fibrillization of α -synuclein protein in cellular and mouse models	Erin	McConnell	Carleton University
P183	Ion Chromatography as a Tool for Characterization and Method Development of Cationic siRNA Formulations	Nicholas	McHugh	UMass Chan Medical School
P184	Clinical Testing of a First-in-Class Antagomir for the Treatment of Metastatic Cancer of Multiple Tissue Origins	Zdravka	Medarova	TransCode Therapeutics, Inc.
P185	Significance of Pharmacokinetic Modeling in Early and Late-Stage Clinical Development of an Antisense Oligonucleotide	Meena	Meena	Stoke Therapeutics
P186	Strategies to Improve Assay Sensitivity for Bioanalysis of Therapeutic Oligonucleotides through Ligand Binding Assays	Vaibhav	Mehta	Altasciences
P187	Preclinical study of mutant allele-specific silencing by gapmer antisense oligonucleotides in a mouse model of SPTLC1-related hereditary sensory neuropathy	Jinhong	Meng	Genetics and Genomic Medicine Department, Great Ormond Street Institute of Child Health, University College London, 30 Guilford Street, WC1N 1EH
P188	Identification and Prevention of Therapeutic Oligonucleotide-Induced Acute Toxicity in the Central Nervous System	Rachael	Miller	Umass Chan Medical School
P189	Deep learning-based design of cell-targeting ligands enables functional siRNA delivery in multiple extrahepatic tissues	Chad	Miller	Nosis Bio
P190	Dissecting the mechanism of prion disease-specific toxicity of antisense oligonucleotides using transcriptomics	Eric	Minikel	Broad Institute
P191	Dynamin-2 (DNM2) Targeting Antisense Oligonucleotides as a Potential Treatment for Centronuclear Myopathy (CNM)	Anindita	Mitra	Sarepta Therapeutics
P192	Improved Double-Stranded DNA Recognition via Invasion with Multiple Pairs of Parallel-Stranded Peptide Nucleic Acids (PNA)	Naoya	Mochizuki	Nagoya University
P193	Deprotection of dGib nucleotide residues in synthetic oligonucleotides by aqueous ammonia and methylamine: a kinetic study	Mikhail	Guzaev	AM Chemicals
P194	TRIDENT – a novel universal solid support for oligonucleotide synthesis	Mikhail	Guzaev	AM Chemicals
P195	AI and ML based algorithm for accurate prediction of functional fully modified siRNAs	Kathryn	Monopoli	RNA Therapeutics Institute - UMass Chan Medical School

P196	Antisense oligonucleotide-mediated exon skipping treatments for neurodevelopmental disorders associated with tandem-repeat domain missense variants in ANKRD17	Jack	Morgan	LUMC
P197	RNase H1-Mediated Oncotherapeutics: MicroRNA-Induced Intracellular Construction of Long DNA/RNA Heteroduplex	Kunihiko	Morihiro	The University of Tokyo
P198	Brain Delivery of Anti-Sense Oligonucleotides Using the Transport Vehicle Technology: Model-based Analysis of Preclinical Data and Clinical Translation Strategy	Arash	Moshkforoush	Denali Therapeutics
P199	Therapeutic Targeting of a Pathological MicroRNA in Skeletal and Cardiac Muscle Diseases	Anders	Naar	Elenae Therapeutics, Inc. and University of California, Berkeley
P200	DNA Origami as a Vehicle for Efficient and Precise Extra-hepatic Delivery of Therapeutic Oligonucleotides	Natalia	Navarro	IQAC-CSIC
P201	A novel selection method generating nuclear localization aptamers	Kaito	Nitatouge	Graduate School of Pharmaceutical Sciences, Osaka University
P202	de novo Synthesis of Nucleosides and Nucleoside Analogues	Matt	Nodwell	Simon Fraser University
P203	Accelerating Development of SINEUPs for Treatment of Haploinsufficiency-Associated Developmental and Epileptic Encephalopathies	Athena	Olszewski	St. Jude Children's Research Hospital Graduate School
P204	Antigen footprint governs activation of the B cell receptor	Marjan	Omer	MIT
P205	Multivalent display of EpCAM aptamers on DNA nanostructures for targeted siRNA delivery to triple-negative breast cancer cells	Marjan	Omer	MIT
P207	Unveiling the Role of MicroRNAs in Colorectal Cancer	Sonya	Ostashevskaya-Gohstand	UT Southwestern
P208	Higher-order structure evaluation of anti-PD-1 aptamer by combining circular dichroism spectroscopy and statistical testing method.	Taiji	Oyama	JASCO Corporation
P209	RNAi therapeutics against childhood cancer	Caroline	Palm Apergi	Department of Laboratory Medicine, Karolinska Institutet
P210	Oligophore and Semaphore for extrahepatic delivery of therapeutic RNA	Covadonga	Paneda	Altamira Therapeutics
P211	One Gene, Two Therapies: Targeting SCN2A Nano-Rare Mutations with Individualized Antisense Oligonucleotides	Catherine	Parisien	n-Lorem Foundation
P212	Overcoming Preclinical Development Challenges on the Path to Develop a Targeted Treatment for a Patient with Familial Dysautonomia	Catherine	Parisien	n-Lorem Foundation
P213	Mechanistic Underpinnings of Cas9 Guide RNA Ribose Requirements	Adrian	Pater	Wake Forest University School of Medicine
P214	Shuttle Peptide Mediates the Delivery of Phosphorodiamidate Morpholino Oligomers in Mucus Hypersecretion Models	Mia	Pelletier	Laval University
P215	Evaluation of HDAC inhibitors to increase dystrophin rescue in DMD following exon skipping therapy.	Micky	Phongsavanh	Université Saint-Quentin-en-Yvelines (UVSQ)
P216	An Empirical Approach to the Characterization of an Antisense Oligonucleotide Synthesis Process	Thomas	Pickel	Biogen
P217-V	Preliminary Biodistribution and Safety of an Unconjugated Reporter PMO at High Doses in the Central Nervous System of Mice	Ilanthe	Pitout	Murdoch University
P221	Polyvalent DNA-encoded libraries (DELs) strategy enabled by a novel crosslinked DNA headpiece conferring improved chemical resiliency.	Julien	Poupart	Institute for Research in Immunology and Cancer
P223	Breaking the Skin Barrier: Novel siRNA Delivery for Dermatological Therapies	Mohamad Omar	Rachid	University of Massachusetts Chan Medical School
P224	tRNA therapeutics to treat stop codon disease	Swetha	Rajasekaran	Alltrna Inc.
P225	Discovery and Optimization of the Pre-Clinical Efficacy of Human PNPLA3-Targeting Short Interfering RNA Molecules (siRNAs) for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis	Vivek	Rajwanshi	Aligos Therapeutics, Inc

P226	Two Pre-clinical Short Interfering RNA Molecules (siRNAs) Targeting Human HSD17B13- for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis	Vivek	Rajwanshi	Aligos Therapeutics, Inc
P227	Extrahepatic Gene Editing and Knockdown Using the Non-Viral Fusogenix Proteolipid Vehicle	Arun	Raturi	Entos pharmaceuticals
P228	Using ADAR1 chimeric eCLIP to understand the on-target and off-target behaviors of RNA editing oligonucleotides	Zhiji	Ren	Korro Bio
P229	ELISA-like hybridization assay for the detection of therapeutic oligonucleotides	Nicholas	Rice	ADViRNA
P230	Synthetic Development and Application of Mesyl Phosphoramidate Fragments in Solid-Phase Synthesis	Brad	Robertson	Biogen
P231	Novel 3-Component Zwitterionic Amino Lipid Nanoparticles for mRNA Delivery	Joshua	Robinson	UT Southwestern Medical Center
P232	Chemical Engineering of Therapeutic Oligonucleotides: Role of the Non-natural Backbone	Vella	Ross	UMass Chan Medical School
P233	Alternative routes of administration for CNS delivery of oligonucleotides: Potency and exposure comparison between ICV, IT-catheter and IT-direct delivery in non-human primates	Kaushambi	Roy	Eli Lilly
P234	Enhancing Aptamer Diversity for Targeted Therapeutics Using DNA-Encoded Polymer Libraries	Christopher	Saab	McGill University
P235	Antibacterial activities of peptide nucleic acids targeting Salmonella Penicillin-Binding Proteins	Mohamed Elfateh	Salem	Department of Animal Science, Macdonald Campus, McGill University
P236	Quantifying and Mitigating Motor Phenotypes Induced by Antisense Oligonucleotides in the Central Nervous System	Samantha	Sarli	RNA Therapeutics Institute - UMass Chan Medical School
P237	Exploring Ribose Modification Tolerance in the Coding Region of mRNA	Emmanuel	Sasu	Biochemistry Department, Wake Forest University School of Medicine
P238	Development and Clinical Progress of RAG-01, a Novel saRNA Targeting p21 for Non-Muscle Invasive Bladder Cancer Treatment	Ian	Schacht	Ractigen Therapeutics
P239	Developing life-saving oligonucleotide-based therapies for H-ABC Leukodystrophy.	Yalda	Sedaghat	Evotec SE
P240	Optimization and Application of the Endosomal Escape Vehicle (EEV™) Platform for Enhanced Delivery of Oligonucleotides to Skeletal and Cardiac Muscle	Xiulong (Mark)	Shen	Entrada Therapeutics
P241	A new structure of N-(tert-butyl)guanidine-bridged nucleic acid, GuNA™[tBu] with a highly stable protecting group and its application in antisense oligonucleotides	Ajaya	Shrestha	Luxna Biotech Co., Ltd.
P242	Engineering CIRT5 to Rebalance Protein Expression from mRNA in Haploinsufficiencies	Riley	Sinnott	University of Chicago
P243	Selective ASO-based JAK2 inhibitor for the treatment of myeloproliferative disorders	Sandra	Smieszek	Vanda Pharmaceuticals
P244	Translating IGHMBP2 variants with a patient-specific neuromuscular junction system: Personalized medicine rescue.	Sandra	Smieszek	Vanda Pharmaceuticals
P245	Sustainability of lifetime dosing with ASOs for rare diseases: The need for scalable national models	Rachel	Smith	UK Platform for Nucleic Acid Therapies
P246	Utilizing NanoBRET to Study RNA Modifications and Binding Dynamics	Richard	Somberg	Promega Corporation
P247	Enhancing Peptide and PMO Delivery to Mouse Airway Epithelia by Chemical Conjugation with the Amphiphilic Peptide S10	Al Halifa	Soultan	Feldan Therapeutics
P248	Mechanistic characterization of enhanced delivery oligonucleotide (EDO) platform	Mangala	Soundarapandian	PepGen
P249	Combining 27-mer siRNAs for simultaneous knockdown of APP and MAPT for Alzheimer's Disease	Jack	Stahl	University of Miami Center for Therapeutic Innovation
P250	Preclinical development of a JAK1 siRNA for the treatment of inflammatory diseases in dogs	Qi	Tang	University of Massachusetts Chan Medical School

P251	Explainable AI for Predictive Modeling of Drug Properties	Disa	Tehler	Abzu
P253	Application of antisense oligonucleotide therapy to rescue dystrophin (DMD) in the central nervous system of the mdx23 mouse model of Duchenne muscular dystrophy	Konstantina	Tetorou	The Dubowitz Neuromuscular Centre, UCL Great Ormond Street Institute of Child Health
P254	New Synthetic Methodology Enables Rapid Screening and Discovery of Hydrazone-Based Fluorescent Nucleobase Analogues	Matthias	Thijs	McGill University
P255	Sustainable Methods for Oligonucleotide Synthesis	James	Thorpe	McGill University
P256	Oligonucleotide Bioconjugation in Solution via Aminooxy Click Chemistry (AOCC)	Mark Neil	Tolentino	Alnylam Pharmaceuticals
P257	Optimization of reaction conditions for Oligo-peptide conjugation reaction	Kelley	Tolliss	LGC Axolabs
P258	Plasma Protein Binding Assessment and Comparison of GalXC™ and GalXC-Plus™ siRNA Using Electrophoretic Mobility Shift Assay	Hung-Chun	Tung	Novo Nordisk
P259	Using G-ASOs to Inhibit MAOB Translation in Neuronal Cells for Parkinson's Disease Therapy	Marc-Antoine	Turcotte	Université de Sherbrooke
P260	A new type of siRNA that can knockdown the gene with single nucleotide mutation discriminating the wild-type gene for clinical application	Kumiko	Ui-Tei	The University of Tokyo
P261	Expanding RNAi to lungs, kidneys, and spleen via Selective ORgan Targeting (SORT) siRNA lipid nanoparticles	Amogh	Vaidya	University of Texas Southwestern Medical Center
P262	Universal Detection Reagents Bind Chemical Modifications for Biodistribution, Localization, and Quantification of Oligonucleotides Independent of Nucleic Acid Sequence	Allison	Van Camp	Rockland Immunochemicals, Inc.
P263	Exon skipping in ex vivo human skin highlights the potential of antisense oligonucleotide-mediated exon skipping as systemic treatment for recessive dystrophic epidermolysis bullosa	Peter	van den Akker	Division for Biological Chemistry and Drug Discovery, School of Life Sciences, University of Dundee
P264	Deciphering the impact of toxic antisense oligonucleotide (ASO) gapmer off-target (OT) RNA degradation on OT protein level	Daniel	van Leeuwen	Clinical Pharmacology and Safety Sciences, Biopharmaceuticals R&D, AstraZeneca
P265	Personalized antisense oligonucleotide screening for a Stargardt disease patient carrying the deep-intronic c.859-506G>C ABCA4 variant using human in vitro models.	Edwin	van Oosten	Department of Pediatrics, Radboud university medical center
P266	Targeting Polo-Like Kinase 1 against childhood cancer	Daria	Varyvoda	Karolinska Institute
P267	Rational design of chimeric antisense oligonucleotides with limited linkage modifications for efficient splice switching.	Rakesh	Veedu	Murdoch University
P268	Safety of antisense oligonucleotide therapy: A systematic review and meta-analysis on adverse events in clinical studies.	Cisse	Vermeer	University Medical Center Gronigen, Department of Genetics
P269	Splice switching of COL7A1 for Epidermolysis Bullosa by using tcDNA-oligonucleotides	Daniela	Vieira Rodrigues	UVSQ - Université Paris Saclay
P270	Toward complete modification of SpyCas9 guide RNAs	Kimanh	Vu	Umass Chan Medical School
P271	Construction of Chimeric Artificial Nucleic Acids (CANA) for Pancreatic Cancer Treatment by Inhibiting the Transcription Factor BACH1: Molecular Design Strategy Based on in vitro and in vivo Analysis	Takehiko	Wada	IMRAM, Tohoku University
P272	Enhanced Purity of sgRNA and pegRNA via 5'-DOT Hydrophobic Phosphoramidite	A.	Wagh	UMass Chan Medical School
P273	RNA-targeting antisense oligonucleotide therapeutics for actionable disease-causing variants of rare genetic disorders.	Htoo	Wai	University of Southampton
P274	Characterising antibodies targeting antisense oligonucleotide (ASO) modifications for quantification of in vitro intracellular trafficking and in vivo biodistribution	Xiao	Wan	Nucleic Acid Therapy Accelerator

P275	Antisense oligonucleotides targeting linked-SNPs provide allele-specific knockdown of a dominant-negative SPTAN1 pathogenic variant in a complex genetic region	Christiana	Wang	Baylor College of Medicine
P276	Exploring small RNA isoforms as a treatment for Idiopathic Pulmonary Fibrosis (IPF)	Johnny	Wang	Gatehouse Bio
P277	ATR-FTIR spectroscopy: A versatile tool for incoming quality control measurements	Jonas	Watzel	BioSpring
P279	Synthesis of Oligonucleotide Conjugates by Diselenide-Selenoester Ligation Deselenization / Alkylation	Christopher	Wilds	Concordia University
P280	Design, Synthesis, and Evaluation of 1'-C,3'-O-Bridged D-Altritol Nucleic Acids	Takao	Yamaguchi	Graduate School of Pharmaceutical Sciences, Osaka University
P281	Development of a Microflow LC-MS/MS Method for Enhanced Quantitative Analysis of Antisense Oligonucleotides in Human Plasma	Hao	Yang	Thermo Fisher Scientific
P282	Small Molecule-Templated DNA Hydrogel: Improved Nuclease Resistance and Gene Silencing through Supramolecular Assembly of Nucleobase-Mimicking Molecules with Nucleic Acids	Chihyu	Yao	McGill University
P283	Evaluation of branched lipid conjugated siRNA by intracerebroventricular and intrathecal injection	Shinichi	Yokota	Shionogi & Co. Ltd.
P284	Novel synthetic route for 1'-C,3'-O-propylene-bridged altritol nucleic acid phosphoramidites bearing a purine nucleobase	Tomoki	Yoshimura	Graduate School of Pharmaceutical Sciences, Osaka University
P285	Mechanistic Insights and Innovative Technologies to Neurotoxicity in Nucleic Acid Therapies Targeting CNS diseases.	Kotaro	Yoshioka	Department of Neurology and Neurological Science, Tokyo Medical and Dental University
P286	Deciphering and improving antisense oligonucleotide safety in the CNS	Faouzi	Zarrouki	Neuroscience and Immuno-inflammation Therapeutic Area (NITA), Servier Research Institute
P287	Identification of Potent siRNA Hits for an Immunology Gene Target and Demonstration of CD71 Centyrin- siRNA Conjugate Preparation, Analysis and In Vitro and In Vivo Activity	Thomas	Zengeya	Aro Biotherapeutics
P288	Individualized Antisense Oligonucleotide Therapy for a Patient with Posterior Column Ataxia with Retinitis Pigmentosa (PCARP)	Boxun	Zhao	Boston Children's Hospital
P289	Comparison of modified T7 RNAPs to develop a simplified, cost effective, robust mRNA production process	Constance	Zhong	Providence Therapeutics
P290-V	The UK Platform for Nucleic Acid Therapy for Rare Diseases – the UPNAT Consortium	Haiyan	Zhou	University College London
P291	Exon skipping in DMD using newly developed Bulge-type RNA-DNA hetero-G4 inducing ASOs	Ryo	Iwase	Tokyo Medical and Dental University
P292	Personalized Splice-modulating Antisense Oligonucleotides	Robert	Thompson	Boston Children's Hospital, Mass General Brigham
P293	TraffikGene: a versatile platform for nucleic acid delivery	Alberto	Fuertes	Universidad de Santiago de Compostela
P294	Cardioprotective Effect and Mechanisms of Action of a Novel Antisense Oligonucleotide	Andr�s	Makkos	Semmelweis University, Dept. of Pharmacology and Pharmacotherapy